Ascendis Pharma (NasdaqGS:ASND) has drawn investor attention after recent trading showed the stock down about 9% over the past month, with a smaller decline over the past 3 months and relatively flat year to date.

For Ascendis Pharma, the recent 8.9% 1 month share price decline sits on top of a softer 7 day return and leaves the year to date share price return only slightly lower overall. This hints that momentum has been fading rather than building as investors reassess both growth prospects and risk around the current US$244.20 share price.

If you are looking beyond Ascendis Pharma for ideas in a similar space, it can be useful to compare it with other healthcare companies using AI. A good starting point is the 42 healthcare AI stocks

So is this recent pullback in Ascendis Pharma pointing to a cooler view on the business itself, or is it mostly sentiment moving around a US$244.20 share price? The next step is to see what the valuation suggests.

Most Popular Narrative: 19.8% Undervalued

Based on the most followed narrative, Ascendis Pharma's fair value sits at $304.60 compared with the recent $244.20 close. This frames the current pullback as a valuation gap rather than just short term noise.

Ascendis Pharma focuses on developing and commercializing long acting therapies for rare endocrine and growth disorders using its TransCon technology platform.

Regulatory and commercial rollout of TransCon CNP in achondroplasia, including potential U.S. approval and ex U.S. launches, targets an area of clear unmet need. Once weekly dosing and benefits beyond linear growth are a focus, which can support incremental revenue growth and scale benefits on selling and marketing expenses.

Curious what sits behind that $304.60 fair value for Ascendis Pharma. The narrative leans on rapid top line expansion, rising profitability and a future earnings multiple that is still above the wider biotech group. Want to see which specific growth and margin paths have been built into that story.

Result: Fair Value of $304.60 (UNDERVALUED)

However, the Ascendis Pharma narrative also carries real risk if YORVIPATH uptake slows or if TransCon CNP approvals, labels, or adoption fall short of current assumptions.

Next Steps

If this mix of potential upside and real risk around Ascendis Pharma feels finely balanced, do not wait for consensus to form before you look closer. Review the full breakdown of the 4 key rewards and 2 important warning signs

Looking for more investment ideas beyond Ascendis Pharma?

If you want a fuller watchlist to sit alongside Ascendis Pharma, use the Simply Wall St Screener to surface clear, data driven ideas that fit your style.

• Target potential bargains with stronger fundamentals by reviewing the 51 high quality undervalued stocks that currently stand out on quality and price.
• Focus on steadier potential by scanning the 79 resilient stocks with low risk scores that rate well on resilience and business risk factors.
• Get ahead of the crowd by checking the screener containing 17 high quality undiscovered gems that combine solid fundamentals with lower current visibility.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.